All In Biotech

BLA 050114 · Allerquest

Pre-Pen

Benzylpenicilloyl Polylysine · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Jan 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Jul 25, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

1 Phase 3, 1 recruiting

FAERS reports

35

11 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2024.

INDICATIONS AND USAGE: PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 25, 1974 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • PRE-PEN · BENZYLPENICILLOYL POLYLYSINE 60UMOLAR · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Benzylpenicilloyl Polylysine" as an intervention, any sponsor and status, largest first.

All 2 trials
  • AllerQuest LLCIndustry

    NCT01818336 · 481 participants · Start Dec 2012 · Primary completion Jun 2013

    Drug: Penicillin skin test kit · For: History of IgE Dependent Reaction to a Penicillin Product

    Sites: Homewood, Alabama; Tucson, Arizona; Walnut Creek, California · 13 sites in all

  • Massachusetts General HospitalAcademic, hospital or other

    NCT06406114 · 300 participants (planned) · Start May 5, 2025 · Primary completion Jul 1, 2028

    Drug: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge and 3 more · For: Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity and 4 more

    Sites: Scottsdale, Arizona; San Francisco, California; Boston, Massachusetts · 6 sites in all

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus12
  • false negative investigation result9
  • urticaria6
  • anaphylactic reaction4
  • skin test positive4
  • erythema3
  • feeling hot3
  • maternal exposure during pregnancy3
  • throat tightness3
  • drug hypersensitivity2
  • dyspnoea2
  • exposure during pregnancy2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20161
20185
20196
20207
20215
20221
20232
20244
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Allerquest

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.